A survey to understand disease activity measures and viable treatment targets in psoriatic arthritis

The GRAPPA Working Group is continually striving to optimise the assessment and management of psoriatic arthritis (PsA). As part of these ongoing efforts, the group previously issued two independent surveys; one to healthcare professionals with an interest in PsA and one to patients with PsA.

The objective of these surveys was to explore current disease activity measures and how they can be improved to define a set of measures which better assess disease activity in PsA. The results from the patient survey (139 participants) were presented in the GRAPPA Working Group meeting on Saturday 11th February 2017 where the patient perspective was presented to help inform the discussion on how the disease should be assessed and monitored. This has led to a number of different recommendations and the GRAPPA Working Group would appreciate a few minutes of your time to gain your opinion on their recommendations.

Any information you provide us with will be treated as confidential and you will remain anonymous. You have the right to refuse to answer a question or completely withdraw from the survey at any time.

 
20% of survey complete.

T